Positive results announced in Phase II trial to treat common warts

Aclaris Therapeutics Inc. recently announced the results of its Phase II clinical trial, WART-201, during which the topical solution A-101 has shown positive results in treating the common wart (verruca vulgaris).
 
“We are extremely pleased with these results,” Aclaris President and CEO Dr. Neal Walker said. “This is an important milestone for our A-101 development program and substantiates the clinical value of our proprietary formulation of A-101 Topical solution. Based on these results, we plan to continue the development of the 45 percent concentration of A-101 as a potential treatment for common warts.”
 
A-101 is a high-concentration formulation of hydrogen peroxide that is being evaluated as a treatment for common warts. Warts are caused by the human papillomavirus (HPV), which infects the top layer of skin. While warts are benign growths, they are unattractive and contagious. If approved by the U.S. Food and Drug Administration (FDA), A-101 would be the only prescription treatment for warts.
 
The trial included 98 patients and 90 completed the eight weekly treatments. It compared the effects of a 40 percent concentration, 45 percent concentration and placebo topical in treating common warts. The 45 percent concentration showed significant results in the Physician's Wart Assessment (PWA) and in clearing common warts.